



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/567,682

02/09/2006

Yoshiharu Wakao

03970503PUS1

4473

2292 7590 04/25/2008
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747

EXAMINER

STELLING, LUCAS A

ART UNIT

PAPER NUMBER

1797

NOTIFICATION DATE

DELIVERY MODE

04/25/2008

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

Office Action Summary	Application No. 10/567,682	Applicant(s) WAKAO ET AL.	
	Examiner Lucas Stelling	Art Unit 1797	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 March 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-9 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1797

4. Claims 1, and 3 - 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over JP Pub. No. 05-000910 ("Shuzo") in view of JP Pub. No. 2002-086155 ("Keisuke") in further view of JP Pub No. 01-094997 ("Kozo") and further in view of Ikuta, et al, *Biofouling Control Using a Synergistic Hydrogen Peroxide and Ferrous Ion Technique*, 49th Annual Meeting, International Water Conference, 1998 ("Ikuta"), as evidenced by the Merck Index Monograph No. 01900.

5. Shuzo teaches a method for treating ship ballast water (**Shuzo English translation abstract**) in which organisms viable in the ship ballast water are exterminated by adding to the ship ballast water hydrogen peroxide or a compound producing hydrogen peroxide in an amount such that a hydrogen peroxide concentration comes to be 10 to 500 mg/L (**Shuzo English translation abstract**). With contact times of 3-40 hours (**Shuzo English translation abstract**). Shuzo is different than the claims in that Shuzo does not teach the use of ferrous ions, catalase, or iodine.

6. As to the use of ferrous ions, Ikuta teaches that FeSO₄ was used at 0.25ppm (**Ikuta p. 449 col. 2 lines 25-30**) in combination with hydrogen peroxide (**Ikuta p. 449 col. 1**) to prevent biofouling in seawater (**Ikuta Abstract**). Ikuta teaches that the use of FeSO₄ with hydrogen peroxide has a synergistic effect when used to control mussels (**Ikuta Conclusion**). Therefore it would have been obvious to a person of ordinary skill in the art at the time of invention to use FeSO₄ with the method of Shuzo to produce a synergistic effect when controlling organisms with hydrogen peroxide in the ballast water.

Art Unit: 1797

7. As to the use of catalase, Kozo teaches the use of catalase, in concentrations of 0.01ppm or more, with hydrogen peroxide in controlling marine organism fouling (**Kozo English translation abstract**). The Merck Index teaches that catalase is an enzyme, which promotes the decomposition of hydrogen peroxide to water and oxygen (**Merck Index Monograph 01900**). Therefore it would have been obvious to a person of ordinary skill in the art the time of invention to provide catalase in the method of Shozu to control marine organism fouling and to promote the decomposition of excess hydrogen peroxide.

8. As to the use of iodine, Keisuke teaches the use of iodide ions in concentrations between 0.00016 mol/L and 1 mol/L, or 20mg/L to 127×10^3 mg/L (**Keisuke [0021] teaches the concentration, and Keisuke [0039] potassium iodide is used as an iodine source**) with peroxide or peracetic acid (a peroxide supplier) (**Keisuke [0020]**). Keisuke also teaches that iodide is an effective disinfectant (**Keisuke [0024], “germicidal action of hypobromous acid ... and/or hypiodous acid”**). Therefore, it would have been obvious to a person of ordinary skill in the art at the time of invention to supply iodine in the method of Shuzo to control organisms in ship ballast water because iodine is a known disinfectant usable with peracetic acid.

As to claim 5, The Merck Index teaches that bovine liver catalase is known at least as early as 1962 (**The Merck Index monograph 01900**), and further teaches that catalase for commercial use is obtained from animal livers. Therefore it would be within the

understanding of a person of ordinary skill in the art to use bovine catalase in the method of claim 5.

9. As to claim 7, Shuzo teaches a method for controlling the organism growth in ship ballast water. Shozu teaches that seawater is an available source of water for a ship and can be used to adjust the concentration of peroxide (**Shozu [0012]**).

Therefore, it would have been obvious to a person of ordinary skill in the art at the time of invention to dilute the compound mixture to the desired concentration using available freshwater or seawater in order to adjust the peroxide concentration.

10. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Shuzo, Keisuke, Kozu, Ikuta, and the Merck Index as applied to claim 1 above, and further in view of U.S. Patent No. 5,256,701 to Tamura et al ("Tamura").

11. The combination of Shuzo, Keisuke, Kozu, Ikuta, and the Merck Index is different from claim 2 in that the low end of the range taught in Keisuke for iodine concentration is 20mg/L, but claim 2 is drawn to a method where the range is between 0.1mg/L to 10mg/L. Tamura teaches that the biocidal properties of iodine are tied to its concentration, and that the amount of free iodine needed is normally determined by the loss of free iodine due to disinfection consumption and the end use of the disinfection composition (**Tamura col. 1 lines 35-57**). Therefore, it would have been obvious to a person of ordinary skill in the art at the time of invention to provide iodine in the range between 0.1mg/L and 10mg/L as the product of routine experimentation based on the

Art Unit: 1797

disinfection and consumption parameters of disinfecting ship ballast water. MPEP 2144.05 (II)(A).

Response to Arguments

1. Applicant's arguments filed 03-27-08 have been fully considered but they are not persuasive.
2. Applicant's first argument is that a person of ordinary skill in the art would know not to add ferrous ions to a hydrogen peroxide solution. The prior art of record teaches the synergistic use of hydrogen peroxide with ferrous ions **(See Ikuta abstract, "...hydrogen peroxide (chemical A) was tested alone, and synergistically, with a ferrous ion additive (Chemical B); abstract, " ... which indicated that the synergistic effect of the two Chemicals (A with B) can reduce biofouling by six times,")**. A person of ordinary skill in the art, given Shuzo and Ikuta, would be motivated to combine hydrogen peroxide with ferrous ions in order to achieve the art recognized synergistic effect.
3. Applicant's second and third arguments are that the decomposition reaction of hydrogen peroxide is undesired in that it decreases the extermination effects thereof. It has not been established that the decomposition reaction is entirely undesirable. The claims in issue do not specify an order for addition of compounds, and Kozo teaches the use of catalase with hydrogen peroxide; and, as taught by the Merck Index, catalase decomposes hydrogen peroxide. Keisuke teaches the use of iodine with a peroxide producer. A person of ordinary skill would understand to use the catalase or iodine to consume excess peroxide before releasing the ballast water.

Art Unit: 1797

4. Applicants fourth argument is that the combination of hydrogen peroxide and ferrous ion, iodine, or catalase produces unexpected results. As to ferrous ion, the synergistic effect is known. And as to iodine, or catalase, the fact that applicant has recognized another advantage which would flow naturally from following the suggestion of the prior art cannot be the basis for patentability when the differences would otherwise be obvious. See *Ex parte Obiaya*, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985).

5. Applicant's fifth and sixth arguments are that the invention maintains a specific amount of oxygen in the ballast and that the examples show superior effects. Applicant has shown no nexus between the claim limitations and these features of the invention pointed out in the specification, it is noted that the features upon which applicant relies are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

6. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

Conclusion

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP

§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lucas Stelling whose telephone number is (571)270-3725. The examiner can normally be reached on Monday through Thursday 12:00PM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Duane Smith can be reached on 571-272-1166. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1797

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Matthew O Savage/
Primary Examiner, Art Unit 1797

las